AF
Atle Fund Management AB
13F filer · CIK 0001381843Reported Jul 24, 2026
Net seller this quarter
13F portfolio value$372MU.S. long equity reported on 13F
Positions393 new · 3 closed
Net flow last quarter-$193MBuys minus sells
Top 10 positions weight48.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 24, 202639 positions | |||||
| $35.8M | 9.62% | 0.00% | -24.9% | Q4 2017 | |
| $24.3M | 6.55% | 0.01% | +459.4% | Q1 2016 | |
| $21.7M | 5.84% | 0.00% | -7.5% | Q1 2026 | |
| $16.2M | 4.35% | 0.00% | -40.5% | Q4 2020 | |
| $15.1M | 4.07% | 0.01% | +514.6% | Q1 2021 | |
| $14M | 3.76% | 0.01% | +21.2% | Q4 2022 | |
| $13.7M | 3.68% | 0.03% | -88.2% | Q4 2024 | |
| $13.6M | 3.65% | 0.04% | Not reported | Q2 2017 | |
| $12.3M | 3.31% | 0.07% | -18.7% | Q4 2022 | |
| $11.8M | 3.17% | 0.16% | -48.5% | Q1 2024 | |
| $11.2M | 3.01% | 0.13% | -12.0% | Q2 2024 | |
| $10.9M | 2.93% | 0.08% | +392.0% | Q4 2023 | |
| $10M | 2.70% | 0.00% | -15.7% | Q4 2024 | |
| $9.81M | 2.64% | 0.01% | -65.2% | Q1 2025 | |
| $9.53M | 2.57% | 0.01% | +12.9% | Q4 2022 | |
| $9.5M | 2.56% | 0.01% | -16.8% | Q1 2021 | |
| $9.34M | 2.51% | 0.02% | -3.1% | Q4 2022 | |
| $9.29M | 2.50% | 0.06% | +12.0% | Q4 2022 | |
| $8.93M | 2.40% | 0.08% | -36.1% | Q4 2022 | |
| $8.81M | 2.37% | 0.02% | +32.6% | Q2 2016 | |
| $8.43M | 2.27% | 0.21% | +162.5% | Q1 2024 | |
| $7.75M | 2.09% | 0.07% | +84.1% | Q4 2025 | |
| $6.46M | 1.74% | 0.03% | +12.1% | Q4 2025 | |
| $6.44M | 1.73% | 0.16% | +142.4% | Q1 2025 | |
| $6.25M | 1.68% | 0.01% | +262.0% | Q4 2022 | |
| $6.22M | 1.67% | 0.03% | -40.1% | Q4 2025 | |
| $6.21M | 1.67% | 0.12% | +563.7% | Q1 2026 | |
| $5.83M | 1.57% | 0.00% | -3.8% | Q2 2014 | |
| $5.61M | 1.51% | 0.01% | -78.3% | Q1 2014 | |
| $5.22M | 1.41% | 0.09% | New | Q2 2026 | |
| $5.06M | 1.36% | 0.06% | -9.1% | Q1 2026 | |
| $4.84M | 1.30% | 0.02% | -87.7% | Q4 2022 | |
| BTBCAXBicara Therapeutics Inc. | $4.32M | 1.16% | 0.22% | -87.6% | Q1 2025 |
| $3.52M | 0.95% | 0.10% | +203.5% | Q4 2025 | |
| $3.49M | 0.94% | 0.07% | -76.4% | Q3 2025 | |
| $3.19M | 0.86% | 0.11% | -59.3% | Q2 2025 | |
| $2.91M | 0.78% | 1.52% | +390.5% | Q4 2025 | |
| $2.3M | 0.62% | 0.58% | +2406.7% | Q4 2025 | |
| $1.97M | 0.53% | 0.14% | New | Q2 2026 | |
| Q1 2026Reported May 11, 202639 positions | |||||
| $26.8M | 8.67% | 0.00% | +27.6% | Q4 2017 | |
| $22.9M | 7.40% | 0.00% | -82.7% | Q1 2016 | |
| $14.4M | 4.67% | 0.01% | -23.2% | Q4 2022 | |
| $12.1M | 3.92% | 0.00% | +3.2% | Q4 2024 | |
| $11.9M | 3.86% | 0.00% | New | Q1 2026 | |
| $11.9M | 3.84% | 0.06% | -21.2% | Q4 2022 | |
| $11.2M | 3.61% | 0.01% | Not reported | Q1 2021 | |
| $10.4M | 3.35% | 0.01% | Not reported | Q4 2020 | |
| $9.58M | 3.09% | 0.01% | Not reported | Q4 2022 | |
| $9.44M | 3.05% | 0.02% | +217.4% | Q1 2025 | |
| $9.4M | 3.03% | 0.02% | -69.8% | Q4 2023 | |
| $9.4M | 3.03% | 0.32% | +118.3% | Q1 2024 | |
| $9.27M | 2.99% | 0.00% | -77.7% | Q1 2021 | |
| $9.08M | 2.93% | 0.31% | +584.4% | Q4 2024 | |
| $8.84M | 2.86% | 0.00% | -62.8% | Q4 2022 | |
| $8.72M | 2.81% | 0.00% | Not reported | Q4 2023 | |
| $8.27M | 2.67% | 0.02% | Not reported | Q4 2022 | |
| $8.24M | 2.66% | 0.15% | Not reported | Q2 2024 | |
| $7.97M | 2.57% | 0.03% | -28.3% | Q4 2025 | |
| $7.85M | 2.54% | 0.09% | -5.4% | Q4 2022 | |
| $7.16M | 2.31% | 0.00% | -5.6% | Q2 2014 | |
| $6.79M | 2.19% | 0.13% | +11.0% | Q4 2022 | |
| $6.6M | 2.13% | 0.01% | -1.3% | Q2 2016 | |
| $6.26M | 2.02% | 0.07% | -40.6% | Q1 2025 | |
| $5.96M | 1.92% | 0.05% | +249.6% | Q4 2025 | |
| $5.51M | 1.78% | 0.08% | -51.9% | Q1 2024 | |
| $5.14M | 1.66% | 0.29% | +237.8% | Q3 2025 | |
| $4.78M | 1.54% | 0.04% | Not reported | Q4 2025 | |
| $4.77M | 1.54% | 0.05% | +363.1% | Q1 2014 | |
| $4.01M | 1.30% | 0.04% | -68.1% | Q4 2025 | |
| $3.63M | 1.17% | 0.02% | New | Q1 2026 | |
| $3.49M | 1.13% | 0.08% | New | Q1 2026 | |
| $3.19M | 1.03% | 0.28% | +123.6% | Q2 2025 | |
| $3.05M | 0.99% | 0.02% | -92.8% | Q4 2025 | |
| $2.77M | 0.90% | 0.00% | Not reported | Q4 2022 | |
| $2.64M | 0.85% | 0.15% | +1371.1% | Q4 2022 | |
| BTBCAXBicara Therapeutics Inc. | $2.32M | 0.75% | 1.78% | +950.3% | Q1 2025 |
| STSLNOSoleno Therapeutics Inc | $2.21M | 0.71% | 0.17% | +43.8% | Q3 2024 |
| $1.62M | 0.52% | 0.31% | -68.1% | Q4 2025 | |
| Q4 2025Reported Feb 6, 202639 positions | |||||
| $33.5M | 10.67% | 0.00% | -16.4% | Q4 2017 | |
| $24.7M | 7.89% | 0.01% | +17.5% | Q4 2020 | |
| $20.6M | 6.57% | 0.01% | +21.7% | Q1 2016 | |
| $17.3M | 5.53% | 0.01% | +10.2% | Q4 2022 | |
| $13.4M | 4.29% | 0.09% | -7.6% | Q4 2022 | |
| $12.6M | 4.03% | 0.01% | +13.3% | Q1 2025 | |
| $12.3M | 3.92% | 0.00% | +33.3% | Q4 2024 | |
| $10.8M | 3.45% | 0.07% | -19.1% | Q4 2022 | |
| $10.4M | 3.32% | 0.01% | +29.4% | Q1 2021 | |
| $10.4M | 3.31% | 0.01% | +25.4% | Q4 2022 | |
| $9.43M | 3.01% | 0.01% | +17.9% | Q4 2022 | |
| $8.45M | 2.70% | 0.01% | Not reported | Q1 2021 | |
| $8.35M | 2.66% | 0.12% | -19.8% | Q4 2022 | |
| $8.03M | 2.56% | 0.01% | -16.9% | Q2 2016 | |
| $7.31M | 2.33% | 0.06% | Not reported | Q4 2023 | |
| $7.18M | 2.29% | 0.05% | +5.7% | Q4 2024 | |
| $7.17M | 2.29% | 0.00% | +58.7% | Q4 2023 | |
| $7.08M | 2.26% | 0.17% | -4.2% | Q1 2024 | |
| $7M | 2.23% | 0.04% | New | Q4 2025 | |
| $6.91M | 2.21% | 0.17% | +1.8% | Q1 2024 | |
| $6.78M | 2.16% | 0.15% | -4.1% | Q2 2024 | |
| $6.67M | 2.13% | 0.12% | +25.3% | Q1 2025 | |
| $6.23M | 1.99% | 0.00% | -35.0% | Q2 2014 | |
| $5.1M | 1.63% | 0.30% | Not reported | Q2 2024 | |
| $4.85M | 1.55% | 0.01% | New | Q4 2025 | |
| $4.82M | 1.54% | 0.01% | -22.5% | Q1 2014 | |
| $4.26M | 1.36% | 0.04% | New | Q4 2025 | |
| $4.17M | 1.33% | 0.09% | +12.6% | Q3 2025 | |
| $3.81M | 1.22% | 0.13% | +5.0% | Q2 2025 | |
| $3.37M | 1.07% | 0.11% | New | Q4 2025 | |
| $3.19M | 1.02% | 0.00% | +6.6% | Q4 2022 | |
| $3.14M | 1.00% | 0.33% | New | Q4 2025 | |
| STSLNOSoleno Therapeutics Inc | $2.9M | 0.93% | 0.12% | +4.3% | Q3 2024 |
| AACLXArcellx, Inc. | $2.72M | 0.87% | 0.07% | +62.1% | Q4 2022 |
| $2.64M | 0.84% | 0.01% | -21.9% | Q4 2022 | |
| $2.33M | 0.74% | 0.44% | Not reported | Q4 2023 | |
| BTBCAXBicara Therapeutics Inc. | $1.87M | 0.60% | 0.20% | -45.3% | Q1 2025 |
| $873K | 0.28% | 0.61% | -38.9% | Q1 2024 | |
| $710K | 0.23% | 0.98% | New | Q4 2025 | |
| Q3 2025Reported Nov 4, 202538 positions | |||||
| $3.02M | 11.19% | 0.00% | -3.8% | Q4 2017 | |
| $2.26M | 8.40% | 0.01% | +6.0% | Q4 2020 | |
| $1.53M | 5.67% | 0.10% | +16.1% | Q4 2022 | |
| $1.43M | 5.32% | 0.01% | +15.6% | Q1 2016 | |
| $1.4M | 5.18% | 0.01% | +11.9% | Q4 2022 | |
| $1.1M | 4.07% | 0.00% | +24.4% | Q4 2024 | |
| $963K | 3.57% | 0.09% | +5.6% | Q4 2022 | |
| $949K | 3.52% | 0.01% | -9.1% | Q2 2016 | |
| $936K | 3.47% | 0.01% | +6.2% | Q1 2025 | |
| $921K | 3.42% | 0.01% | +6.8% | Q2 2014 | |
| $898K | 3.33% | 0.01% | -31.3% | Q4 2022 | |
| $894K | 3.31% | 0.01% | -17.1% | Q4 2022 | |
| $805K | 2.99% | 0.15% | +11.3% | Q2 2024 | |
| $791K | 2.93% | 0.15% | +109.3% | Q4 2022 | |
| $739K | 2.74% | 0.01% | -27.0% | Q1 2021 | |
| $729K | 2.70% | 0.18% | -12.5% | Q1 2024 | |
| $585K | 2.17% | 0.17% | +23.2% | Q1 2024 | |
| $548K | 2.03% | 0.09% | +18.5% | Q1 2025 | |
| $542K | 2.01% | 0.01% | +14.5% | Q4 2022 | |
| $505K | 1.87% | 0.01% | +13.1% | Q1 2014 | |
| $487K | 1.81% | 0.30% | +5.0% | Q2 2024 | |
| MMRUSMerus N.V. | $480K | 1.78% | 0.06% | -19.9% | Q4 2022 |
| STSLNOSoleno Therapeutics Inc | $432K | 1.60% | 0.11% | +48.4% | Q3 2024 |
| $423K | 1.57% | 0.05% | +3.7% | Q4 2024 | |
| $414K | 1.53% | 0.00% | -42.2% | Q4 2023 | |
| $363K | 1.35% | 0.01% | Not reported | Q4 2022 | |
| BTBCAXBicara Therapeutics Inc. | $342K | 1.27% | 0.37% | +38.3% | Q1 2025 |
| $321K | 1.19% | 0.13% | +85.3% | Q2 2025 | |
| $298K | 1.10% | 0.00% | Not reported | Q4 2022 | |
| $269K | 1.00% | 0.16% | +6.7% | Q3 2021 | |
| ABRNAMAvidity Biosciences, Inc. | $240K | 0.89% | 0.04% | New | Q3 2025 |
| $236K | 0.87% | 1.40% | Not reported | Q1 2024 | |
| AACLXArcellx, Inc. | $224K | 0.83% | 0.04% | Not reported | Q4 2022 |
| $203K | 0.75% | 0.01% | Not reported | Q3 2024 | |
| $202K | 0.75% | 0.44% | +5.8% | Q4 2023 | |
| $195K | 0.72% | 0.09% | New | Q3 2025 | |
| $167K | 0.62% | 0.10% | Not reported | Q3 2024 | |
| $129K | 0.48% | 0.08% | Not reported | Q4 2024 | |
Premium opens every quarter this fund has filed